A randomized-controlled trial of ischemia-free liver transplantation for end-stage liver disease

• DOI: 10.1016/j.jhep.2023.04.010
• Publication Date: 2023-04-20T20:32:43Z
• Authors: Zhiyong Guo; Qiang Zhao; Zehua Jia; Changjun Huang; Dongping Wang; Weiqiang Ju; Jian Zhang; Lu Yang; Shanzhou Huang; Maogen Chen; Xiaofeng Zhu; Anbin Hu; Yi Ma; Linwei Wu; Yinghua Chen; Ming Han; Yunhua Tang; Guodong Wang; Linhe Wang; Lifen Li; Wei Xiong; Zhiheng Zhang; Yuekun Shen; Zhaoxia Tang; Caihui Zhu; Xiaoxiang Chen; Xiaoguang Hu; Yiwen Guo; Honghui Chen; Yihao Ma; Tao Zhang; Shunwei Huang; Ping Zeng; Simei Lai; Tielong Wang; Zhitao Chen; Jinlong Gong; Jia Yu; Canhui Sun; Chang Li; Haiyi Tan; Yao Liu; Yuqi Dong; Chengjun Sun; Bing Liao; Jun Ren; Zhenhai Zhou; Schlegel Andrea; Nashan Björn; Changjie Cai; Fengqiu Gong; Jian Rong; Wenqi Huang; Xiangdong Guan; Pierre-Alain Clavien; Tullius G. Stefan; Jiefu Huang; Xiaoshun He
• Keywords: Clinical endpoint

Ischemia-reperfusion injury (IRI) has thus far been considered as an inevitable component of organ transplantation, compromising outcomes, and limiting availability. Ischemia-free transplantation is a novel approach designed to avoid IRI, with the potential improve outcomes.